Phase IIb BMS Arthritis Drug Meets Endpoint

barbara.lempert Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American ...

Bullish Actelion once again hots up as a possible takeover target

John Carroll Now that Actelion has safely walked away with an FDA approval of its new lung disease drug Opsumit, Bloomberg's Real M&A team has put it back on its list of top ...

McKesson buying Celesio for $5.4B as wholesalers seek pricing leverage

Eric Palmer Drugmakers long ago went global, and now drug wholesalers see the need to follow the same strategy. Months after AmerisourceBergen hooked up with Walgreen's and Alliance ...

ImmunoGen 1Q FY2014 Revenue Up

mia.burns ImmunoGen, Inc. Reports First Quarter Fiscal Year 2014 Financial Results and Provides Quarterly Update Quarterly Conference Call Today at 8:00 am ET− WALTHAM, Mass.–(BUSINESS ...

Public Citizen goes on a witch hunt at the FDA

John Carroll FierceBiotech has covered its share of stories on money scandals and drug development, but this is a tempest in a proverbial tea pot. FierceBiotech News

FDA again finds itself playing role as pain med police

Eric Palmer The FDA's move to put tighter controls on combo pain drugs like Vicodin that contain hydrocodone with over-the-counter painkillers like aspirin have it again balancing ...

CHMP Grants Opsumit Positive Opinion for PAH

mia.burns Actelion receives positive CHMP opinion for Opsumit (macitentan) for the long-term treatment of pulmonary arterial hypertension •    CHMP adopts positive opinion ...

Study: R&D for neglected diseases still negligible

Damian Garde Despite some high-profile commitments from some of the industry's largest innovators, R&D for some of the world's most deadly neglected diseases remains underfunded ...

Japan’s frustrated Eisai loses fight with DEA

Eric Palmer Japan's Eisai, which lashed out this week at the U.K.'s cost watchdog as too restrictive, has lost its bid to force the DEA to schedule Fycompa so it can get it ...

Synexus Opens New Regional Center in Eastern Europe

mia.burns Synexus continues to build in Eastern Europe, opening a new regional center to support global clinical trials   Synexus has today opened a regional office for Eastern ...

Can a change of scenery revive AstraZeneca’s stilted R&D?

Damian Garde AstraZeneca is in the midst of transferring its global R&D base to a $ 500 million campus in Cambridge, U.K., shouldering up with the famed institution in hopes of ...

Humira sales, up 19%, continue to carry AbbVie

Eric Palmer What is better than having the best-selling drug in the world.? Having the best-selling drug and seeing its sales sprint ahead by more than 19% for a quarter. FiercePharma ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS